Formulations of a somatostatin modulator

Inventors

Burke, Gerald • Yates, Ian • Bulovsky, Hannah • Kyburz, Kyle • Tyler, Clayton

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11266641-B1

Patent

Publication Date

2022-03-08

Expiration Date


Abstract

Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The invention discloses a spray-dried solid dispersion comprising Compound A, or a pharmaceutically acceptable salt or solvate thereof, dispersed in a polymer matrix formed from a pharmaceutically acceptable polymer. The disclosed dispersions include amorphous drug and identify HPMCAS-M and PVP/VA 64 as polymer options. The patent also describes tablets containing the dispersion and conventional pharmaceutical ingredients.

The supplied partial content does not include the background section, so it does not explicitly describe the problem being solved. It reports formulation and pharmacokinetic findings, including physical stability of a selected PVP/VA 64 formulation and less sensitivity of the SDD tablets to elevated gastric pH or proton-pump inhibitors than the HMG capsule. It also reports more dose-proportional exposure for SDD tablets.

Claims Coverage

Claims 1 and 13 are independent claims presenting two inventive features. The supplied text for claim 16 expressly identifies it as a tablet of claim 13, so it is dependent rather than an independent claim.

Spray-dried solid dispersion in a polymer matrix

Claim 1 covers a spray-dried solid dispersion comprising 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof, dispersed in a polymer matrix formed from a pharmaceutically acceptable polymer.

Tablet containing the monohydrochloride compound in a polymer matrix

Claim 13 covers a tablet comprising the specified monohydrochloride compound, or a solvate thereof, dispersed in a polymer matrix formed from a pharmaceutically acceptable polymer; one or more pharmaceutical ingredients selected from diluents, disintegrants, disintegrant aids, lubricants, and glidants; and optionally one or more film coating agents.

The independent claims cover the drug-polymer spray-dried solid dispersion and a tablet formulation containing the monohydrochloride compound in a polymer matrix with selected pharmaceutical ingredients. The supplied dependent claims further specify polymer and excipient choices, formulation composition, dosage form, and bioavailability-related conditions.

Stated Advantages

The selected PVP/VA 64 formulation maintains physical stability.

The SDD tablets are less sensitive to elevated gastric pH or proton-pump inhibitors than the HMG capsule.

The SDD tablets show more dose-proportional exposure.

A shorter post-dose fasting period is feasible.

Documented Applications

Oral treatment of acromegaly.

Oral treatment of neuroendocrine tumors.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.